Yale Cancer Center carefully invests funds to launch new areas of cancer research. Current funding opportunities are listed below.


December 13, 2018 – internal competition deadline

January 22, 2019 – deadline for institution’s letter of intent

February 21, 2019 – sponsor’s deadline

May 2019 – sponsor’s review of applications

September 1, 2019 – funding starts



F99/K00 RFA-CA-19-002  

Frequently Asked Questions



Stipends: Stipends are provided as an allowance to help defray living expenses during the research training.  The stipend level for F99 predoctoral fellows is the same as the F31 Ruth L. Kirschstein National Research Service Award (NRSA) fellows for up to 2 years.  See https://www.cancer.gov/grants-training/training/funding/f31.

Tuition and Fees: NCI will contribute the combined cost of tuition and fees at the rate in place at the time of award, at the same level as the F31.

Institutional Allowance: Provided to defray cost of fellowship expenses such as health insurance, research supplies, equipment, books, and travel to scientific meetings and is the same as the F31, plus a one-time additional $1,500 in the first year to attend a mandatory NCI-sponsored conference.


 The F99 fellow becomes eligible for the K00 award phase once the individual has been offered and accepted a postdoctoral appointment and must submit a K00 transition application at that time.


Yale University in its entirety may nominate one (1) candidate.


The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students who have demonstrated potential and interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.


  • May be a citizen or a noncitizen national of the United States, have been lawfully admitted for permanent residence or be a non-U.S. citizen with a valid U.S. visa. For applications submitted on behalf of non-U.S. citizens with valid U.S. visas, the visa status during each phase of the F99/K00 award must allow the PD/PI to conduct the proposed research at the applicant institution. For the F99 phase of the award, the applicant F99 institution is responsible for determining and documenting, in the nomination letter, that the applicant's visa will allow the applicant to remain in the U.S. to complete the F99 phase of the award, and that there are no known obstacles that would prevent the applicant from obtaining a visa for the K00 phase.
  • Must have a baccalaureate degree and be currently enrolled as a graduate student in the 3rd or 4th year of a mentored PhD or equivalent research degree program (e.g., DrPH, ScD) in the biomedical, behavioral, or clinical sciences at a domestic institution.
  • Must be at the dissertation research stage of training at the time of award, and must show evidence of high academic performance in the sciences and commitment to a career as an independent cancer research scientist.
  • The F99/K00 award may not be used to support studies leading to the MD, DDS, or other clinical, health-professional degree (e.g., DC, DMD, DNP, DO, DPM, DVM, ND, OD, AuD). Students matriculated in a dual-degree program (e.g. MD/PhD, DO/PhD, DDS/PhD, or DVM/PhD) are not eligible for the F99/K00 program.
  • F99 awardees are required to pursue their research training on a full-time basis, normally defined as 40 hours per week or as specified by the sponsoring institution in accordance with its own policies.


  • For NIH requirements for application formatting click here.
  • Cover Letter (include the name, title, and institution of three (3) to five (5) referees who are not a sponsor or co-sponsor).
  • NIH Biographical Sketch following the Pre-doctoral Fellowship format. Click here for a sample.
  • Biosketches for Sponsor and Co-Sponsor (not the same as referees)
  • Project Summary (30 lines of text)
  • Specific Aims (1 page)

All applicants must use these two Aims:

Aim 1: The Dissertation Research Project. Provide a detailed description of the research to be completed in the F99 phase.

Aim 2: The Postdoctoral Research Direction.  Identify the research direction to be pursued for the K00 phase.

 Incomplete applications, applications from candidates ineligible for the competition, and applications not in the required format will not be forwarded to the review panel.  The Yale Cancer Center Award Panels review applications received by the deadline and will select Yale’s nominee.  All applicants will be notified of the panel’s decision as soon as possible after the review.  


  • It should summarize your project succinctly, outlining its importance and relevance. 
  • It should provide an overview of the project, the goals, the hypotheses to be tested, and approaches and techniques to be used.
  • You will want to outline briefly the things you plan to accomplish during the project period; be sure to describe concisely the research design and the methods to be used in the project.
  • Avoid jargon.
  • When you’re finished writing the specific aims, ask your sponsor to proofread.


Christine Holmberg 



Joann Sweasy, PhD


Yale Cancer Center Internal Grants Program



January 2, 2019 – internal deadline

February 1, 2019 – sponsor deadline


Award Overview: https://www.damonrunyon.org/for-scientists/application-guidelines/clinical-investigator

Application Guidelines: https://www.damonrunyon.org/for-scientists/application-guidelines/clinical-investigator/forms

Clinical Investigator Award Committee: https://www.damonrunyon.org/for-scientists/committees/clinical-investigator

Current/Former Recipients and their Projects: https://www.damonrunyon.org/for-scientists/awardees/investigators


$200,000 direct costs per year for 3 years. (Total: $600,000 direct costs)

The fund will also retire up to $100,000 of any medical school debt still owed by the awardee.

*See funding limitations in Award Overview https://www.damonrunyon.org/for-scientists/application-guidelines/clinical-investigator


Yale University in its entirety, including the Cancer Center, may nominate five (5) candidates.


The Foundation seeks to reverse the trend of decreasing numbers of young physicians undertaking clinical cancer research. It supports the most promising early career physician-scientists willing to devote their efforts to the development and application of new diagnostic approaches and therapeutic strategies for cancer and cancer prevention through clinical investigation.

The Foundation is seeking independent investigators engaged in disease-oriented research that is characterized by exceptional innovation and creativity, supporting candidates whose work is likely to meaningfully impact the practice of cancer medicine.

Preference is given to research that adheres to the “Handshake Rule,” meaning that the physician will conduct research studies that directly involve patients.

For the purposes of this award, the Foundation’s definition of clinical research is:

  • Patient-oriented research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator directly interacts with human subjects.This area of research includes:  • patient-based studies of mechanisms of human disease, diagnostic and therapeutic interventions, • clinical trials, and • development of new technologies for the detection, treatment and prevention of human cancers.
  • Epidemiologic and behavioral studies.
  • Outcomes research and health services research.

Excluded from this definition are in vitro studies that utilize human tissues but do not deal directly with patients. It is necessary to know the identity of the patient(s) from whom the cells or tissues under study are derived.


  • The applicant must be a U.S. citizen or permanent legal resident.
  • The applicant must hold an independent assistant professor position or equivalent. 
  • The applicant must have received an MD or MD/PhD degree(s) from an accredited institution, completed their subspecialty training and be U.S. Board eligible.
  • The applicant must hold a valid, active U.S. medical license at the time of application.
  • The applicant must apply within the first five (5) years of their initial full faculty appointment (Cut-off date: July 2014). Adjunct or acting positions are not eligible.
  • Candidates holding or awarded R01s at the time of application are not eligible to apply.
  • The applicant must commit to spending 80% of their time conducting research. [In rare unique circumstances, the CIA Committee may consider an applicant with a very modest reduction of 80% protected time if their Department Chair can provide a compelling reason explaining why a waiver of the 80% requirement should be granted, what percentage of effort will be guaranteed, and what safeguards will be put in place to make sure the individual’s research will not be compromised by their clinical/administrative activities.]
  • The applicant is required to apply in conjunction with a Mentor who is established in the field of clinical translational cancer research, cancer prevention and/or epidemiology and can provide the critical guidance needed during the period of the award.  No more than two Damon Runyon Clinical Investigators will be funded to work with the same Mentor at any given time.
  • Candidates may apply up to three times during this eligibility period. 
  • Only one application will be accepted from a Mentor per review session (including Co-Mentorships).


The internal application must include the following items (Format: Application format requirements: 11-pt Arial, Helvetica, Georgia, or Palatino Linotype font, singlespaced, minumum of .5” margins):

  • Current curriculum vitae (CV)  or NIH Biographical Sketch (five-page maximum) 
  • List of all current and pending support, including information on costs (if none, state none) 
  • Your proposed research project (five-page maximum).  References may be provided on one additional page. 
  • A letter of recommendation from your Department Chair or if more appropriate, from your Section Head, Program Director, or mentor(s) (Letter must be on Yale letterhead and signed)

Incomplete applications, applications from candidates ineligible for the competition, and applications not in the required format will not be forwarded to the review panel.  The Yale Cancer Center review committee review applications received by the deadline and will select Yale’s nominee(s).  All applicants will be notified of the panel’s decision as soon as possible after the review.    

Tips for preparing your five-page description

• The description should summarize your project succinctly, outlining its importance and its relevance to the specific competition for which you are applying. 

• It should provide a broad overview of the project, the goals, the hypotheses to be tested, and approaches and techniques to be used. 

• You will want to outline briefly the specific aims, i.e. the things you plan to accomplish during the project period; be sure to describe concisely the research design and the methods to be used in the project. 

• Avoid jargon. 

• When you’re finished writing the two-page description, ask someone outside your specialty to read your description to make sure that it is intelligible to a physician or scientist working in an area of research other than your own.  

NOTE: All applications received are acknowledged to the applicant.  If you have not received acknowledgement of receipt of your application within one week of submission, please contact Christine Holmberg immediately to confirm receipt for the Damon Runyon award.  




January 2, 2019 (11:59pm) – internal deadline 

February 8, 2019 (5:00pm) – sponsor deadline  


Program Homepage: http://www.marykayfoundation.org/Pages/CancerGrantProgram.aspx General FAQ:  http://www.marykayfoundation.org/Pages/FAQ.aspx Current/Former Recipients and their Projects: https://www.marykayfoundation.org/cancergrantrecipients Grant Application: The 2019 application link will be provided to the nominee; it is not posted on the sponsor’s website.  


Up to $100,000 for up to 2 years to cover the costs of the proposed research project. (Total: $100,000 direct and indirect, 15% indirect costs). 


One candidate can be nominated –from the School of Medicine.  


The Foundation’s focus is on funding innovative translational research in ovarian, uterine, breast or cervical cancer. Translational research is broadly defined as research that will provide a scientific link between laboratory research and the clinic. Ultimately, such research would lead to improvement in diagnosis, prognosis, prevention, or treatment of cancer.  


• Open to all junior and senior ladder faculty (Asst, Assoc, full-time Prof)

• U.S. citizenship is not required.

• Time to be devoted to research: not restricted.  


2017, Sidi Chen …, 2016, David Spiegel … 2012, Alfred Bothwell … 2010, Frank Slack … 2009, Lynne Regan  


  • 5 Page Proposal the proposed research project including specific aims, research design, and figures should not be longer than 5 pages (8.5 x 11).  References cited and collaboration letters do NOT count toward the 5 page limit.  Please use 12 point Times New Roman font type with one inch margins.  Start with specific aims, preliminary results and research design (maximum 5 pages).  This should be followed by references cited ( 2 page max), and essential letters of collaboration (all included as one document).  Other support, and NIH Biosketch/CV are uploaded separately. 
  • NIH Biosketch
  • Other Financial Support
  • Letters of Support